Kythera Biopharmaceuticals, Inc (KYTH)

[tedkov]

BUYOUT OF KYTHERA - LAW FIRM SEEKS HIGHER PRICE
fyi….

New York, New York/June 17, 2015 - A leading national securities and shareholder rights law firm announces that it is investigating the acquisition of Kythera Biopharmaceuticals on behalf of its shareholders. Allergan has agreed to acquire KYTHERA in a cash and equity transaction valued at $75 per KYTHERA share, or approximately $2.1 billion. The fixed-value transaction consideration will be payable 80 percent in cash and 20 percent in new AGN shares issued to KYTHERA shareholders.

The investigation concerns whether shareholders are receiving the maximum value for their shares considering the company's future growth prospects. Indeed, analysts have projected the stock is worth at least $85 per share. The investigation further seeks to determine whether management may have entered into this transaction for their own self interests at the expense of the company's shareholders.

If you are a shareholder of Kythera and would like to receive additional information regarding this matter including how your shares can be eligible for a higher price at no cost or expense please contact us toll free at 800.511.7037.